BNP Paribas Financial Markets’s Entrada Therapeutics TRDA Stock Holding History

BNP Paribas Financial Markets’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$700K	Sell	95,044 -86,104	-48%	-$826K	﹤0.01%	3566
2026 Q1	$2.29M	Buy	181,148 +179	+0.1%	+$2.05K	﹤0.01%	2579
2025 Q4	$1.86M	Buy	180,969 +32,757	+22%	+$276K	﹤0.01%	2665
2025 Q3	$860K	Buy	148,212 +145,167	+4,767%	+$849K	﹤0.01%	3224
2025 Q2	$20.5K	Sell	3,045 -5,189	-63%	-$41.7K	﹤0.01%	4595
2025 Q1	$74.4K	Buy	8,234 +4,910	+148%	+$61.2K	﹤0.01%	4149
2024 Q4	$57.5K	Buy	+3,324	New	+$60.2K	﹤0.01%	4375
2022 Q4	–	Sell	-198	Closed	-$3.12K	–	4605
2022 Q3	$3.12K	Buy	+198	New	+$2.51K	﹤0.01%	4298

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

BNP Paribas Financial Markets's TRDA Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Entrada Therapeutics (TRDA) stake by 48% in Q2 2026, selling an estimated $826K and leaving 95,044 shares worth $700K. The position accounts for ﹤0.01% of the portfolio, ranked #3566.

BNP Paribas Financial Markets first reported a position in TRDA in Q3 2022 and has held it in 8 quarters since. The position peaked at $2.29M in Q1 2026. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

BNP Paribas Financial Markets held 95,044 shares of Entrada Therapeutics worth $700K as of Q2 2026.
BNP Paribas Financial Markets sold 86,104 Entrada Therapeutics shares in Q2 2026, an estimated $826K.
Entrada Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3566 holding.
BNP Paribas Financial Markets first reported a position in Entrada Therapeutics in Q3 2022 and has held it in 8 quarters since.
BNP Paribas Financial Markets's Entrada Therapeutics position peaked at $2.29M in Q1 2026.
129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.